

Matthew J Lamarche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5548429/publications.pdf>

Version: 2024-02-01

38
papers

3,107
citations

218381

26
h-index

288905

40
g-index

40
all docs

40
docs citations

40
times ranked

3080
citing authors

#	ARTICLE	IF	CITATIONS
1	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. <i>Nature</i> , 2016, 535, 148-152.	13.7	674
2	Evolution of a Gram-Scale Synthesis of (+)-Discodermolide. <i>Journal of the American Chemical Society</i> , 2000, 122, 8654-8664.	6.6	239
3	Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7773-7782.	2.9	229
4	Ribosomally Synthesized Thiopeptide Antibiotics Targeting Elongation Factor Tu. <i>Journal of the American Chemical Society</i> , 2009, 131, 5946-5955.	6.6	165
5	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517.	15.2	155
6	Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2376-2387.	2.9	134
7	Gram-Scale Synthesis of (+)-Discodermolide. <i>Organic Letters</i> , 1999, 1, 1823-1826.	2.4	133
8	Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13578-13594.	2.9	111
9	Dual Allosteric Inhibition of SHP2 Phosphatase. <i>ACS Chemical Biology</i> , 2018, 13, 647-656.	1.6	109
10	Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. <i>Nature Communications</i> , 2018, 9, 4508.	5.8	106
11	Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. <i>Clinical Cancer Research</i> , 2021, 27, 342-354.	3.2	88
12	The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. <i>Chemistry and Biology</i> , 2001, 8, 843-855.	6.2	82
13	6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1793-1802.	2.9	61
14	Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1781-1792.	2.9	58
15	Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4459-4462.	1.4	56
16	Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2. <i>Biochemistry</i> , 2016, 55, 2269-2277.	1.2	55
17	Solution Structure of (+)-Discodermolide. <i>Organic Letters</i> , 2001, 3, 695-698.	2.4	52
18	Discovery and Characterization of Aminopiperidinecoumarin Melanin Concentrating Hormone Receptor 1 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5888-5891.	2.9	50

#	ARTICLE	IF	CITATIONS
19	Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6479-6485.	1.4	43
20	4-Aminothiazolyl Analogues of GE2270 A: Antibacterial Lead Finding. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2517-2521.	2.9	38
21	Antibacterial Optimization of 4-Aminothiazolyl Analogues of the Natural Product GE2270 A: Identification of the Cycloalkylcarboxylic Acids. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8099-8109.	2.9	37
22	SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. <i>Scientific Reports</i> , 2021, 11, 1399.	1.6	37
23	Design, Synthesis, and Evaluation of Carbamate-Substituted Analogues of (+)-Discodermolide. <i>Organic Letters</i> , 2005, 7, 311-314.	2.4	35
24	Antibiotic Optimization and Chemical Structure Stabilization of Thiomuracin A. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6934-6941.	2.9	34
25	Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2368-2380.	1.9	34
26	Discodermolide analogues as the chemical component of combination bacteriolytic therapy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 3623-3626.	1.0	33
27	Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHR1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2621-2627.	1.0	28
28	Design, Synthesis, and Evaluation of Analogues of (+)-14-Normethyldiscodermolide. <i>Organic Letters</i> , 2005, 7, 315-318.	2.4	27
29	Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. <i>Oncotarget</i> , 2020, 11, 265-281.	0.8	27
30	A novel approach to oligocyclopropane structural units. <i>Tetrahedron Letters</i> , 1997, 38, 2057-2060.	0.7	24
31	Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3468-3475.	1.0	23
32	Design, synthesis and cytotoxicity of 7-deoxy aryl discodermolide analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2335-2338.	1.0	21
33	4-Aminothiazolyl analogs of GE2270 A: Design, synthesis and evaluation of imidazole analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3210-3215.	1.0	20
34	2-Alkyloxazoles as potent and selective PI4KIII ² inhibitors demonstrating inhibition of HCV replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3714-3718.	1.0	20
35	Identification of ortho-amino benzamides and nicotinamides as MCHR1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4174-4179.	1.0	18
36	Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. <i>ELife</i> , 2021, 10, .	2.8	17

#	ARTICLE	IF	CITATIONS
37	Gram-Scale Synthesis of (+)-Discodermolide. <i>Organic Letters</i> , 2000, 2, 1983-1983.	2.4	16
38	Antibacterial and Solubility Optimization of Thiomuracin A. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6920-6928.	2.9	14